Browse the evidence

Cholecystokinin (CCK) acts as a primary intestinal satiety signal that regulates food intake via CCK1 receptors on afferent vagal fibers, with its secretion dynamics altered by bariatric surgery but remaining largely unchanged in obesity.

CCK is your body's natural 'fullness' signal from the gut. In obesity, this signal isn't broken; levels are normal. However, bariatric surgery can enhance this signal significantly. Focus on dietary strategies that naturally stimulate CCK release (like protein/fat intake) rather than assuming a hormonal defect.

GLP-1 receptor agonists, SGLT2 inhibitors, and pioglitazone are recommended pharmacotherapies for MASLD/MASH management.

If lifestyle changes are not enough, ask your doctor about GLP-1 RAs, SGLT2 inhibitors, or pioglitazone. These medications can help manage metabolic health and reduce liver disease progression.

Physiological levels of reactive oxygen species (ROS), specifically hydrogen peroxide (H2O2), act as essential signaling molecules that augment insulin sensitivity and glucose uptake in skeletal muscle by inhibiting negative regulators like PTP1B and activating Akt.

Do not assume that high-dose antioxidant supplements improve insulin sensitivity. In healthy or early-stage metabolic contexts, your body relies on low levels of oxidative stress (ROS) to signal insulin to move glucose into muscles. Blocking this signal with excessive antioxidants may actually impair glucose uptake and metabolic adaptation.

Chronic nutrient overload and sedentary behavior lead to 'oxidative distress' (excessive ROS), which causes insulin resistance in skeletal muscle by activating stress kinases (JNK, p38 MAPK) that inhibit insulin signaling.

Insulin resistance in skeletal muscle often starts with chronic nutrient overload, not just sugar. When you consistently consume more energy than you burn, it creates 'oxidative distress' that blocks insulin signals. Managing total energy balance and activity levels is critical to preventing this specific type of metabolic damage.

Mechanistically, GLP-1RA-induced muscle loss is driven by reduced protein intake, negative energy balance, and suppressed mTOR signaling due to lower insulin/IGF-1 levels, rather than direct myotoxicity.

The muscle loss isn't because the drug attacks muscle directly; it's because you eat less, have less energy, and your body's growth signals (like insulin) are lower. This is why eating enough protein and lifting weights is crucial to counteract these natural signals.

Small-molecule GLP-1 receptor agonists (e.g., orforglipron) are pharmacologically inactive in standard wild-type mice due to species-specific receptor binding differences, requiring humanized GLP-1 receptor (hGLP1R) mouse models to accurately predict human metabolic efficacy.

If you are evaluating or using small-molecule GLP-1 drugs (like orforglipron), standard animal testing will not show their effects. These drugs require a humanized receptor to work in mice. This highlights why human clinical trials are essential for this specific class of drugs, as animal models cannot predict their efficacy.

In humanized GLP-1 receptor mice, small-molecule GLP-1 receptor agonists (e.g., orforglipron) produce metabolic effects (weight loss, glucose tolerance) comparable to peptide-based agonists (e.g., semaglutide).

Small-molecule GLP-1 drugs can work as well as peptide drugs in terms of metabolic effects, provided they bind to the correct receptor. This humanized mouse model confirms that oral small-molecule options have the potential to match the efficacy of injectable peptides.

Discontinuation of GLP-1 medications leads to rapid weight regain (up to two-thirds of prior loss) and worsening cardiometabolic health, disproportionately affecting underserved communities.

Stopping GLP-1 medication often leads to regaining up to two-thirds of the weight lost and worsening health. It is crucial to have a sustainable plan for medication access or transition to maintain long-term health.

SGLT2 inhibitors improve mitochondrial function and reduce oxidative stress, contributing to their cardioprotective and renoprotective effects.

SGLT2 inhibitors may help your cells produce energy more efficiently and reduce cellular stress, which protects your heart and kidneys. This is part of why these drugs work beyond just lowering blood sugar.

Altering shoulder position (flexed vs. extended) during elbow flexion resistance training does not influence regional hypertrophy or maximum strength gains when resistance profiles are matched.

If you are doing biceps curls, it does not matter whether you sit on a preacher bench (shoulder flexed) or lie back on an incline bench (shoulder extended), as long as you are lifting heavy enough to fail around 8-12 reps. Both positions will build muscle and strength equally well. Do not waste time switching exercises to 'target' the long head; just pick one and focus on adding weight over time.

Increasing protein intake from 1.0 g/kg/day to 1.6 g/kg/day via egg white or whey protein supplementation does not further enhance physical performance (strength, endurance, aerobic capacity) in recreationally trained males and females undergoing high-intensity functional training (HIFT).

If you are already eating about 1 gram of protein per kilogram of body weight daily, adding extra protein supplements (like whey or egg white) will not make you stronger or more enduring during high-intensity functional training. Focus on your training consistency and total daily protein intake rather than buying extra supplements.

Current anti-obesity medication (AOM) studies frequently misrepresent skeletal muscle mass (SMM) loss by using DXA or BIA to estimate fat-free mass (FFM) or lean mass, which includes bone and non-skeletal tissues, thereby confounding the assessment of clinically significant muscle loss.

When reading studies on weight loss drugs (like GLP-1 agonists) that report 'muscle loss' based on DXA or bioimpedance scales, recognize that these numbers likely overestimate true skeletal muscle loss because they include bone and water. True muscle loss is likely lower than reported in these specific studies. Look for studies using MRI or CT for accurate skeletal muscle quantification.

Semaglutide promotes sex-dependent adipose tissue remodeling, with females showing more pronounced reductions in visceral fat mass and greater potency in locomotor activity increases compared to males.

Men and women may respond differently to semaglutide. This study suggests women might experience greater reductions in visceral fat and larger increases in physical activity compared to men at similar doses. This highlights the importance of sex-specific considerations in obesity treatment.

Incretin-based anti-obesity medications (GLP-1 and GIP/GLP-1 receptor agonists) cause gastrointestinal adverse effects (nausea, diarrhea, constipation) in 65–84% of patients, primarily through delayed gastric emptying and central appetite signaling activation.

If you start a GLP-1 or GIP medication, expect stomach issues like nausea or diarrhea in the first few weeks. This is very common (affecting up to 84% of users). To manage it, start with a low dose and increase slowly. Eat small, low-fat meals, stay hydrated, and avoid spicy or fatty foods. Most symptoms improve as your body adjusts.

Rapid weight loss, whether from very-low-calorie diets or bariatric surgery, significantly increases the risk of gallstone formation (cholelithiasis) due to bile supersaturation and reduced gallbladder motility.

If you lose weight very quickly (e.g., through surgery or extreme dieting), you are at higher risk for gallstones. To prevent this, aim for gradual weight loss. If you have had bariatric surgery, doctors often prescribe Ursodeoxycholic acid (UDCA) for 6 months to prevent gallstones.

Administering GLP-1 receptor agonists (liraglutide or semaglutide) during the proestrus/estrus (P/E) phase of the estrous cycle significantly enhances food intake suppression and body weight loss compared to administration during the metestrus/diestrus (M/D) phase in female rats.

If you are using a GLP-1 medication like semaglutide or liraglutide, your body's natural hormonal cycle may affect how well it works. This research suggests that taking your dose during the weeks when estrogen is highest (typically the first half of the cycle) might lead to greater appetite suppression and weight loss than taking it during other weeks. While more research in humans is needed, you might consider discussing cycle-timing with your provider to see if optimizing the timing of your injections could enhance your results.

Inhibiting PCSK9, NF-κB, and NLRP3 reduces cholesterol and inflammation, providing cardioprotection.

For cardiovascular protection, medications that lower cholesterol (like PCSK9 inhibitors) and reduce inflammation (targeting NF-κB or NLRP3) are effective strategies. These treatments help manage risk factors associated with heart disease and metabolic disorders. Discuss with your healthcare provider if these targeted therapies are suitable for your cardiovascular health.

Dulaglutide, subcutaneous semaglutide, and tirzepatide exhibit comparable risks of severe gastrointestinal adverse events (including acute pancreatitis, biliary disease, bowel obstruction, gastroparesis, and severe constipation) in adults with type 2 diabetes.

If you are choosing between dulaglutide, semaglutide, or tirzepatide for type 2 diabetes, do not expect a significant difference in the risk of serious stomach problems (like pancreatitis or bowel obstruction) between them. They all carry a similar, low risk of severe GI events, though mild nausea or diarrhea is common with all. Your choice should likely be based on efficacy (weight loss/glycemic control), cost, and tolerability of mild side effects rather than fear of severe GI complications.

There are significant research gaps regarding the effectiveness of nutritional interventions for underrepresented populations, specifically women, older adults, and Asian populations.

Be aware that most research on muscle hypertrophy interventions focuses on men and Western populations. If you are a woman, older adult, or from an Asian background, the optimal nutritional strategy may differ, and you should consult a professional for personalized guidance.

Using external momentum (cheat repetitions) during single-joint upper body resistance training produces muscle hypertrophy equivalent to strict technique, despite generating significantly higher volume load.

If you are doing single-joint exercises like bicep curls or tricep pushdowns, you don't need to be rigid about 'strict' form to maximize muscle growth. Using 'cheat' reps (adding momentum) allows you to lift more total volume, which resulted in the same muscle growth as strict reps in this study. However, be cautious of joint stress, especially in your back and hips, as momentum can increase injury risk. Use this technique strategically, perhaps at the end of a set, rather than for every rep, to balance gains with safety.

High carbohydrate intake (highest tertile, median 59.3% energy) is associated with increased MRI-detected vascular brain injury (covert brain infarcts and white matter hyperintensities) and lower cognitive scores (MoCA and DSST) in middle-aged adults.

If you are middle-aged and concerned about brain health, look at your overall macronutrient balance. High carbohydrate intake (over 59% of calories) is linked to more silent brain injuries and lower cognitive scores. Try shifting some of those carbohydrates to healthy fats, like those found in nuts, olive oil, or fish, which were associated with better brain health in this study.

Obesity promotes cancer development by increasing DNA damage and impairing DNA repair mechanisms, while simultaneously activating pro-survival signaling pathways that prevent the elimination of damaged cells.

Maintaining a healthy weight is a critical strategy for reducing cancer risk, not just for metabolic health. Obesity creates a biological environment that damages DNA and prevents the body from fixing those damages, while also protecting damaged cells from dying. Weight management interventions should be viewed as a direct cancer prevention strategy.

Periconceptional exposure to GLP-1 receptor agonists (liraglutide or semaglutide) is associated with an increased risk of preterm birth, but this risk is confined to women using the medication for diabetes treatment and is not observed in women using it for weight management.

If you are using a GLP-1 medication (like Ozempic or Saxenda) and planning pregnancy, talk to your doctor. If you have diabetes, the increased risk of early delivery is likely due to the diabetes, not the drug, so managing your blood sugar is key. If you are using it for weight loss, current large-scale data shows no increased risk of early delivery, which may help alleviate anxiety about inadvertent exposure.

Current herbal anti-obesity clinical trials frequently fail to adhere to international pharmaceutical guidelines, particularly regarding study duration, lifestyle modifications, and safety monitoring.

When evaluating herbal weight loss studies, be aware that many do not follow the same rigorous standards as pharmaceutical trials. Look for studies that include lifestyle modifications, adequate duration, and safety monitoring, as these are often missing.